488 related articles for article (PubMed ID: 29102290)
1. Ion channels as targets to treat cystic fibrosis lung disease.
Martin SL; Saint-Criq V; Hwang TC; Csanády L
J Cyst Fibros; 2018 Mar; 17(2S):S22-S27. PubMed ID: 29102290
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics.
Kunzelmann K; Mall M
Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996
[TBL] [Abstract][Full Text] [Related]
3. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis.
Shei RJ; Peabody JE; Kaza N; Rowe SM
Curr Opin Pharmacol; 2018 Dec; 43():152-165. PubMed ID: 30340955
[TBL] [Abstract][Full Text] [Related]
4. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.
Moore PJ; Tarran R
Expert Opin Ther Targets; 2018 Aug; 22(8):687-701. PubMed ID: 30028216
[
